Gastric Cancer Diagnostics Market to reach a value of USD 1,950.82 million by 2030, at a CAGR of 8.%, Industry Trends

Stomach cancer is a type of cancer that starts in the stomach and spreads throughout the body. The stomach is a muscular pouch that lies immediately below the ribs in the upper part of the abdomen. The stomach takes in and holds the food we eat before breaking it down and digesting it. Stomach cancer, commonly referred to as gastric cancer, can occur in any section of the stomach. Stomach cancers develop in the major section of the stomach in most parts of the world (stomach body). Various diagnostic tests used for the diagnosis of cancer include prescreening tests, biopsy, biomarkers, imaging tests, PET/CT scans, and ultrasound among others.

View Detailed Report" https://www.databridgemarketresearch.com/reports/global-gastric-cancer-diagnostics-market

Cancer is caused by uncontrolled, abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer.

Opportunity

Rise in adoption of automated systems

Cancer is a system and network illness. This indicates that in a cancer cell, certain network-related genes stop working properly. Complex interactions in such gene networks should be addressed in cancer treatment. Artificial intelligence (AI) algorithms, in particular, have been rapidly evolving, which is reflected in oncology's progress.

Machine learning and neural networks are becoming increasingly significant in precision oncology and system medicine. The combination of imaging data with clinical and molecular data opens up a world of possibilities. Radiogenomics, for instance, is a new field focused on multidimensional data processing. It can also benefit from AI advancements.

Thus, the increased adoption of automated systems acts as an opportunity for the growth of this market.

 Drivers

Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma

According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed around the world.

It is projected that the incidence of gastric cancer will rise, due to to aging and increasing population, lifestyle, and socioeconomic change. Striking variations in race, sociocultural norms, behaviors, and dietary trends are reflected in the burden and distribution of cancer in different regions across the globe.

Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics. Thus the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma are expected to drive the growth of the global gastric cancer diagnostics market.

TYPE

Intestinal Or Diffuse Adenocarcinoma

Carcinoid Tumor

Gastrointestinal Stromal Tumor (GIST)

Gastric Lymphoma

Others

On the basis of type, the market is segmented into intestinal or diffuse adenocarcinoma, carcinoid tumor, gastrointestinal stromal tumor (GIST), gastric lymphoma, and others.

STAGE

Stage 0

Stage I

Stage II

Stage III

On the basis of stage, the market is segmented into stage 0, stage I, stage II, and stage III.

Key Players Analysis:

Some of the major players operating in the global gastric cancer diagnostics market are Myriad Genetics, Inc., ACON Laboratories, Inc., Teco Diagnostics., Vela Diagnostics, Abbott, AdvaCare Pharma, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, BIOCEPT, INC., FOUNDATION MEDICINE, INC., DiaSorin S.p.A, Paragon Genomics, Inc., BIOMÉRIEUX, and QIAGEN among others.

North America is expected to dominate the global gastric cancer diagnostics market due to growing prevalence of gastrointestinal tumors. The U.S. dominates the North America region due to the strong presence of key players. Germany dominates the Europe region due to the increasing demand from emerging markets and expansion.

Explore More Reports:

https://dbmrresearchreports.blogspot.com/2024/05/operational-predictive-maintenance.html

https://dbmrresearchreports.blogspot.com/2024/05/tactical-communication-market-will.html

https://dbmrresearchreports.blogspot.com/2024/05/autonomous-vehicle-market-will-exhibit.html

https://dbmrresearchreports.blogspot.com/2024/05/virtual-desktop-infrastructure-vdi.html

About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact Us:
Data Bridge Market Research

Email: 
Corporatesales@databridgemarketresearch.com

This release was published on openPR.